Research programme: integrin antagonists - Targesome
Latest Information Update: 24 Apr 2007
At a glance
- Originator Targesome
- Mechanism of Action Integrin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 22 Apr 2002 Preclinical trials in Cancer in USA (unspecified route)